First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Introduction This was an open-label, dose escalation (3 + 3 design), Phase I study of SOR-C13 in patients with advanced tumors of epithelial origin. Primary objectives were to assess safety/tolerability and pharmacokinetics. Secondary goals were to assess pharmacodynamics and efficacy of SOR-C13. Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418314/
https://www.ncbi.nlm.nih.gov/pubmed/28150073
http://dx.doi.org/10.1007/s10637-017-0438-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418314/
https://www.ncbi.nlm.nih.gov/pubmed/28150073
http://dx.doi.org/10.1007/s10637-017-0438-z

Ejemplares similares